INTRODUCTION {#sec7}
============

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy characterized by arthritis, enthesitis and spondylitis.^[@bibr1]^ The estimated global prevalence of PsA is 133 per 100 000 subjects;^[@bibr2]^ and 0.19% in Europe and 0.01% in the Middle East.^[@bibr3]^ In addition, PsA occurs in up to 30% of patients with psoriasis.^[@bibr4]^ Thus, it can be considered a "disease within a disease". PsA is significantly associated with mortality and the estimated cost to healthcare systems is equivalent to that of rheumatoid arthritis.^[@bibr5]^ The precise etiology of PsA is unclear, but accumulating evidence suggests a key role for genetic factors in PsA with respect to disease susceptibility and expression.^[@bibr6]^

The human leukocyte antigen (HLA) is a polymorphic genetic system encoding the genes involved in the immune response. HLA variation plays a major role in susceptibility to infectious and autoimmune diseases. Various studies have demonstrated a relationship between HLA-C polymorphism and susceptibility to PsA. Reports of an association between the presence of the HLA-C\*06 allele and PsA are consistent;^[@bibr7]-[@bibr10]^ for example, Chandran et al showed that the frequency of HLA-C\*06 was significantly increased (*P*\<.0001) in PsA patients compared with controls, with an odds ratio (OR) of 1.72.5 In contrast, studies from some populations indicate no association between HLA-C\*06 and PsA;^[@bibr11]-[@bibr14]^ for example, Grubić et al demonstrated that the difference in distribution of HLA-C\*06 in both PsA patients and controls was not significant.^[@bibr14]^ Therefore, the association between HLA-C locus polymorphism and PsA remains controversial. We conducted this meta-analysis to estimate the precise association between HLA-C locus polymorphism and PsA in Caucasian populations.

METHODS {#sec1}
=======

Study search strategy {#sec1-1}
---------------------

We conducted a systematic search of studies on the association between HLA-C polymorphism and PsA susceptibility using the PubMed, PMC, Elsevier and Google Scholar databases from 1980 to January 2020, using the search term "((((psoriatic arthritis\[MeSH Terms\]) OR psoriatic arthritis\[Title/Abstract\]) OR PsA\[Title/Abstract\])) AND (((HLA-Cw\[Title/Abstract\]) OR HLA-C\[MeSH Terms\]) OR HLA-C\[Title/Abstract\])". Search results were limited to studies in English.

Inclusion criteria were defined as follows: (i) stud-iesOnly case-control studies (with unrelated participants) that had allele/genotype data that evaluated the association between HLA-C locus polymorphism and PsA susceptibility. Moreover, studies reporting the results of different subpopulations were treated as separate studies with respective OR and 95% CI values assessed independently.

Studies were excluded if they evaluated subjects not of European and Middle Eastern descent (referred to as 'Caucasian' in [**Figure 1**](#F1){ref-type="fig"}), the study was based on family or sibling pairs, the allele/genotype frequencies or numbers were not given, or (iv) review articles, abstracts and books. When the same patient population was reported in numerous publications, only the most complete or recent study was used.

![Study selection diagram. HLA: human leukocyte antigen, PsA: psoriatic arthritis.](0256-4947.2020.338-fig1){#F1}

Data extraction {#sec1-2}
---------------

Using the criteria described above, each manuscript was screened, assessed for quality and data were extracted by two investigators independently with cross-checking. Disagreements were resolved by discussion and consultation with a third researcher. The following data were extracted: first author, year of publication, ethnicity, detection method and the numbers of cases and controls. Eligibility of studies was determined using the Q-Genie tool.^[@bibr15]^ Studies with scores ≤35 were of low-quality, those scoring between 36 and 45 were of moderate quality and those \>45 were high-quality. Genetic data were classified as either allelic or phenotypic.

Statistical analysis {#sec1-3}
--------------------

Data extracted from eligible studies were processed prior to conducting the meta-analysis. Frequency data were translated into numerical values by multiplying the number of samples with values, and numerical data were extracted directly. An I^[@bibr2]^ test was used to evaluate heterogeneity among studies.^[@bibr16]^ A fixed-effects model was used if I^[@bibr2]^\<50%, otherwise, a random-effects model was used.^[@bibr17]^ P values of less than .05 were considered statistically significant. Random-effects model-based subgroup analysis stratified by quality was performed to determine the source of heterogeneity. If quality was not able to explain heterogeneity, univariate random-effects meta-regression was used to explore the heterogeneity, such as publication year, number of cases and case/control ratio. Potential publication bias was intuitively evaluated using funnel plots. Meanwhile, bias was estimated using an Egger\'s test.^[@bibr18]^ Meta-analysis was conducted using STATA 12.0 software.

RESULTS {#sec2}
=======

Included studies {#sec2-1}
----------------

A total of 153 studies were identified after initial review using the search strategies previously described, and 24 articles were retained for meta-analysis ([**Figure 1**](#F1){ref-type="fig"}).^[@bibr7]-[@bibr10],[@bibr19]-[@bibr38]^ After accessing the full-text of the eligible studies, one study^[@bibr19]^ was split into two studies because it contained data for two different subpopulations. Thus, 25 studies were included ([**Table 1**](#tab1){ref-type="table"}).

###### 

Characteristics of the 25 studies included in the meta-analysis.

  First author     Year   Sample size   Typing method   HLA-C/Cw   Data form                                                Q-Genie   
  ---------------- ------ ------------- --------------- ---------- -------------------------------------------------------- --------- ---
  Murray           1980   52            126             Serology   6                                                        P         M
  Woodrow          1985   50            115             Serology   1, 2, 3, 4, 5, 6, 7                                      P         M
  López-Larrea     1990   104           109             Serology   4, 5, 6                                                  P         M
  Gonzalez         1999   65            177             SSOP       01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16           A         M
  Gladman          1999   94            100             SSP        01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17       A         M
  Martin           2002   355           295             SSOP       06                                                       A         M
  González         2002   81            110             SSP        06                                                       P         M
  Al-Heresh        2002   124           101             SSP        06                                                       P         L
  Alenius          2002   84            70              SSP        03, 06                                                   P         M
  Martínez-Borra   2003   74            104             SSP        06                                                       P         M
  Grubić           2004   58            157             SSP        02, 06, 07                                               A         L
  Dobosz           2005   41            80              SSP        01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17, 18   A         H
  Rahman           2005   103           105             SSOP       06                                                       P         M
  Rahman           2005   202           100             SSOP       06                                                       P         M
  Holm             2005   65            371             \-         06                                                       P         L
  Queiro           2006   100           177             SSOP       01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16           A         M
  Ho               2008   453           166             SSOP       06                                                       P         M
  Queiro           2008   120           170             SSOP       06                                                       P         M
  Fojtíková        2009   100           94              SSP        01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17       A         H
  Popa             2011   81            124             SSP        01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17       P         M
  Winchester       2012   359           1000            SBT        01, 02, 04, 05, 06, 07, 12                               P         L
  Cibulova         2013   101           99              SSP        01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17       A         M
  Chandran         2013   678           688             SSOP       01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17, 18   P         H
  Sokolik          2014   50            123             SSP        01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17, 18   A         H
  Queiro           2014   110           110             SSP        06                                                       P         M

SSOP: sequence-specific oligonucleotide probes, SSP: sequence-specific primers, SBT: Sequence-based typing, A: allele counts or frequencies, P: phenotype counts or frequencies, Q-Genie: quality of genetic studies, L: low-quality study, M: moderate-quality study, H: high-quality study. C/Cw: serology/molecular nomenclature.

Results of meta-analysis {#sec2-2}
------------------------

The meta-analyses of OR, 95% CI and I^2^-statistics between HLA-C polymorphism and PsA are presented in [**Table 2**](#tab2){ref-type="table"}. At the allelic level, eight alleles had a significant association with PsA. HLA-C\*02, \*06 and \*12 were associated with an increased risk of PsA, while HLA-C\*03, \*04, \*05, \*07 and \*16 had a decreased risk of PsA. At the phenotypic level, seven phenotypes had a significant association with PsA. Positive associations were observed for HLA-C\*01, \*02, \*06 and \*12. Negative associations were observed for HLA-C\*04, \*14 and \*15. At both the allelic and phenotypic levels, the results showed that HLA-C\*04 played a protective role in PsA while HLA-C\*02, \*06 and \*12 increased the risk for PsA (**[Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}**).

###### 

Associations between HLA-C polymorphism and psoriatic arthritis and subgroup analyses based on quality at allelic and phenotypic levels.

  HLA-C/Cw   Eligible studies   Heterogeneity   Association   Egger\'s Test   High quality   Moderate quality                                                                                                       
  ---------- ------------------ --------------- ------------- --------------- -------------- ------------------ --------------- ------- ------- ------ ------- ------------- --------- ------ ------- ------------- ---------
  01         Allele             7               0.965         0.0             0.533          1.119              0.785-1.596     -0.77   0.474   0.0    1.123   0.603-2.094   0.714     0.0    1.117   0.726-1.720   0.614
  02         Allele             8               0.406         3.1             \<0.001        2.208              1.594-3.060     -1.06   0.330   62.1   2.589   1.449-4.627   0.001     0.0    1.937   1.175-3.193   0.010
  03         Allele             7               0.952         0.0             0.004          0.673              0.512-0.884     -0.79   0.464   0.0    0.605   0.376-0.972   0.038     0.0    0.711   0.509-0.992   0.045
  04         Allele             7               0.457         0.0             0.001          0.663              0.519-0.846     0.35    0.744   0.0    0.569   0.371-0.872   0.010     19.2   0.715   0.531-0.964   0.028
  05         Allele             7               0.954         0.0             0.006          0.609              0.428-0.866     0.99    0.368   0.0    0.777   0.394-1.532   0.466     0.0    0.558   0.369-0.844   0.006
  06         Allele             9               0.073         44.2            \<0.001        2.631              2.200-3.146     1.07    0.321   0.0    3.226   2.198-4.735   \<0.001   63.4   2.568   2.073-3.182   \<0.001
  07         Allele             8               0.054         49.3            \<0.001        0.710              0.597-0.843     0.39    0.709   0.0    0.726   0.534-0.988   0.042     0.0    0.601   0.478-0.755   \<0.001
  08         Allele             7               0.048         52.7            0.956          0.978              0.436-2.190     -0.97   0.378   36.2   1.145   0.441-2.972   0.781     68.1   0.945   0.566-1.577   0.827
  12         Allele             7               0.435         0.0             0.010          1.490              1.102-2.015     -0.55   0.603   0.0    1.291   0.865-1.924   0.211     4.1    1.803   1.132-2.872   0.013
  14         Allele             7               0.988         0.0             0.945          0.979              0.529-1.809     1.22    0.276   0.0    0.865   0.207-3.617   0.843     0.0    1.006   0.510-1.986   0.985
  15         Allele             7               0.987         0.0             0.515          0.828              0.469-1.462     0.81    0.456   0.0    1.248   0.400-3.890   0.703     0.0    0.728   0.376-1.410   0.346
  16         Allele             7               0.558         0.0             0.010          0.503              0.299-0.846     -1.06   0.338   21.8   0.505   0.195-1.304   0.158     0.0    0.503   0.270-0.936   0.030
  17         Allele             5               0.848         0.0             0.058          0.376              0.142-0.993     -2.24   0.111   0.0    0.269   0.068-1.058   0.060     0.0    0.611   0.146-2.565   0.501
  18         Allele             2               0.188         42.2            0.707          1.404              0.239-8.229     \-      \-      \-     \-      \-            \-        \-     \-      \-            \-
  01/1       Phenotype          4               0.842         0.0             \<0.001        1.952              1.489-2.560     -1.50   0.273   \-     1.925   1.288-2.877   0.001     0.0    1.579   0.838-2.978   0.158
  02/2       Phenotype          4               0.045         62.8            0.023          1.791              1.084-2.959     0.09    0.937   \-     1.945   1.348-2.807   \<0.001   80.7   1.149   0.633-2.086   0.647
  03/3       Phenotype          4               0.023         68.5            0.673          0.872              0.462-1.645     0.93    0.451   \-     0.627   0.477-0.824   0.001     69.6   1.040   0.635-1.704   0.877
  04/4       Phenotype          5               0.524         0.0             \<0.001        0.630              0.523-0.760     -0.63   0.575   \-     0.751   0.570-0.990   0.042     0.0    0.564   0.359-0.885   0.013
  05/5       Phenotype          5               0.006         72.6            0.115          0.653              0.384-1.109     -1.27   0.294   \-     1.103   0.819-1.484   0.520     61.9   0.403   0.210-0.773   0.006
  06/6       Phenotype          16              \<0.001       70.7            \<0.001        2.956              2.298-3.804     2.62    0.061   \-     1.715   1.324-2.222   \<0.001   59.1   3.468   2.892-4.159   \<0.001
  07/7       Phenotype          4               \<0.001       85.9            0.330          0.789              0.489-1.272     -0.25   0.825   \-     0.640   0.517-0.792   \<0.001   0.0    0.632   0.404-0.988   0.044
  08         Phenotype          2               0.855         0.0             0.428          0.861              0.596-1.246     \-      \-      \-     \-      \-            \-        \-     \-      \-            \-
  12         Phenotype          3               0.170         43.6            \<0.001        2.253              1.781-2.852     -3.46   0.179   \-     \-      \-            \-        \-     \-      \-            \-
  14         Phenotype          2               0.482         0.0             0.046          0.492              0.245-0.986     \-      \-      \-     \-      \-            \-        \-     \-      \-            \-
  15         Phenotype          2               0.981         0.0             0.005          0.491              0.299-0.806     \-      \-      \-     \-      \-            \-        \-     \-      \-            \-
  16         Phenotype          2               0.411         0.0             0.065          0.685              0.458-1.023     \-      \-      \-     \-      \-            \-        \-     \-      \-            \-
  17         Phenotype          2               0.920         0.0             0.470          1.341              0.604-2.976     \-      \-      \-     \-      \-            \-        \-     \-      \-            \-
  18         Phenotype          1               \-            \-              0.194          7.135              0.368-138.388   \-      \-      \-     \-      \-            \-        \-     \-      \-            \-

HLA: human leucocyte antigen, OR: pooled odds ratio, CI, confidence interval, -: not available.

![Forest plots of the association between HLA-C allele frequencies and psoriatic arthritis (Study a: HLA-C\*02; Study b: HLA-C\*04; Study c: HLA-C\*06; Study d: HLA-C\*12).](0256-4947.2020.338-fig2){#F2}

![Forest plots of the association between HLA-C phenotype frequencies and psoriatic arthritis (Study a: HLA-C\*02; Study b: HLA-C\*04; Study c: HLA-C\*06; Study d: HLA-C\*12).](0256-4947.2020.338-fig3){#F3}

Subgroup analysis and heterogeneity {#sec2-3}
-----------------------------------

When more than four studies had been published, a subgroup analysis of quality was performed ([**Table 2**](#tab2){ref-type="table"}). Sufficient numbers of high- and moderate-quality studies were included and thus, subgroup analysis of low-quality studies is not shown. HLA-C\*02 and \*06 at allelic level and HLA-C\*06 at the phenotypic level were associated with an increased risk of PsA in both high- and moderate-quality subgroups. HLA-C\*03, \*04 and \*07 at the allelic level and HLA-\*04 and \*07 at the phenotypic level were associated with a decreased risk of PsA in both subgroups. Moreover, the quality explained the heterogeneity observed in HLA-C\*07 at the allelic and phenotypic levels because heterogeneity of the subgroups was reduced to zero. Except for the heterogeneity of HLA-C\*07 at the allelic level, sources of heterogeneity for the other studies were explored using univariate meta-regression. However, year of publication, size of case and case/control ratio were not statistically correlated with heterogeneity (*P*\>.05).

Publication bias {#sec2-4}
----------------

The funnel plots showed no evidence of obvious asymmetry. When assessed by the Egger\'s test, no publication bias was found (*P*\>.05).

DISCUSSION {#sec3}
==========

PsA is a chronic immune-mediated inflammatory disorder whereby environmental factors trigger disease in genetically susceptible individuals, with multiple genetic factors contributing to disease susceptibility. PsA is associated with the presence of psoriasis and has a serious impact on the quality of life of patients, an impact that has been demonstrated as lower than that of patients with psoriasis alone.^[@bibr1]^ Several articles demonstrated a correlation between HLA-C and PsA. The most intriguing allele, HLA-C\*06, has already been described in a number of populations with susceptibility to PsA, such as native populations of the Czech Republic,^[@bibr20]^ Spain,^[@bibr21]-[@bibr22]^ Great Britain,^[@bibr9]^ Poland,^[@bibr23]^ Romania,^[@bibr24]^ Sweden^[@bibr25]^ and Newfoundland.^[@bibr19]^ Furthermore, genome-wide association studies have confirmed that the HLA-C region is involved in susceptibility to PsA in populations of European and Middle Eastern descent.^[@bibr1],[@bibr39],[@bibr40]^ The pathogenesis of PsA embraces both innate immunity and a major histocompatibility complex class I (MHC class I) T-cell related cytotoxic response. Additionally, PsA could be viewed as a ''MHC-I-opathy'' due to interactions between MHC class I alleles modifying expression and tissue specific factors.^[@bibr41]^ Nevertheless, no association was found between HLA-C\*06 and PsA in the Croatian population14 or in Canadians from Ontario.19 It is noteworthy that HLA-C\*06 has been shown to be related to PsA in patients with Type I psoriasis in young-onset disease (≤40 years), but not with Type II psoriasis with onset older than 40 years.9 Recent studies have shown that HLA-C\*06 causes early-onset skin disease in both PsA and psoriasis and is not linked to nail or joint diseases.^[@bibr41],[@bibr42]^ Therefore, the conflicting results described above may be explained by the bias of age at psoriasis onset or small sample size. Several investigators focused only on the role of HLA-C\*06 with PsA susceptibility and then only presented the results of HLA-C\*06, ignoring other alleles. The meta-analysis in the present study indicated that besides HLA-C\*06, HLA-C\*02 and \*12 were also factors causing susceptibility to PsA, while HLA-C\*04 was a protective factor for PsA at both allelic and phenotypic levels in all studies of the entire population. The effects of HLA-C\*02 and \*12 may be due to linkage disequilibrium with locus B (B27, B38, B39, B8), and more specifically to the asparagine residue at position 97 (common to B27, B38, B8), as the principal risk element for PsA.^[@bibr1]^ We also found that a number of genes were significantly correlated with PsA at the allelic/phenotypic level but not at the phenotypic/allelic level in whole population studies, such as HLA-C\*07/\*01. The discrepancy is presumably because of the multifactorial nature of PsA and the limitations of the research.

Intra-study heterogeneity is important in meta-analysis. Heterogeneity can be effectively removed when stratified by quality for HLA-C\*07. Moreover, sources of heterogeneity for other factors were explored using univariate meta-regression based on year of publication, size of cohort and case/control ratio. Nevertheless, they were not statistically correlated with heterogeneity. Heterogeneity may arise from the different genetic backgrounds, environmental exposure, bias for cases and controls through selection or unknown variables.

Meta-analysis is a useful strategy to improve analysis and statistical evidence by enlarging the effective sample size. To our knowledge, this is the first meta-analysis that has combined previously-published case-control studies to precisely analyze the association between HLA-C polymorphism and risk of PsA in Caucasian populations. Nevertheless, several inherent limitations of this meta-analysis should be addressed. First, we only considered reports published in English so language bias is inevitable. Studies with negative data may not have been represented because they are more difficult to publish than studies with positive data. Second, the populations studied here were only populations of European and Middle Eastern descent. Thus, the conclusions of this study should be interpreted with caution for individuals of other ethnicities. Multi-ethnic populations should be incorporated into future studies. Finally, we were unable to explore the possibility that results would vary in subjects of different ages, duration of disease and discrepancies in clinical characteristics.

In conclusion, the pooled results suggest a significant association between PsA and HLA-C polymorphism in populations of European and Middle Eastern descent. At the allelic level, HLA-C\*02, \*06 and \*12 were associated with increased risk of PsA, while HLA-C\*03, \*04, \*05, \*07 and \*16 had a decreased association of risk of PsA. At the phenotypic level, seven phenotypes had significant association with PsA. Positive associations were observed for HLA-C\*01, \*02, \*06 and \*12. Negative associations were observed for HLA-C\*04, \*14 and \*15. At both allelic and phenotypic levels, HLA-C\*02, \*06 and \*12 may contribute to susceptibility to PsA, while HLA-C\*04 may confer a protective role against PsA. To further establish these relationships, future studies with larger sample sizes, and more accurate disease subgroup stratification with multi-ethnic sample groups are required.
